111 related articles for article (PubMed ID: 16806433)
1. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer.
Nishio Y; Yamada Y; Kokubo H; Nakamura K; Aoki S; Taki T; Honda N; Nakagawa A; Saga S; Hara K
Urology; 2006 Jul; 68(1):110-5. PubMed ID: 16806433
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer.
Yamada Y; Nakamura K; Aoki S; Taki T; Naruse K; Matsubara H; Tobiume M; Zennami K; Katsuda R; Honda N
BJU Int; 2007 Jan; 99(1):189-95. PubMed ID: 17034504
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
5. Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome?
Yamada Y; Nakamura K; Aoki S; Taki T; Matsubara H; Sai S; Naruse K; Tobiume M; Katsuda R; Zennami K; Honda N; Nakagawa A; Ikeda H
Oncol Rep; 2006 May; 15(5):1309-13. PubMed ID: 16596203
[TBL] [Abstract][Full Text] [Related]
6. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
7. Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer.
Tobiume M; Yamada Y; Nakamura K; Aoki S; Zennami K; Kato Y; Nishikawa G; Yokoi T; Honda N
Prostate; 2011 Mar; 71(4):385-93. PubMed ID: 20812221
[TBL] [Abstract][Full Text] [Related]
8. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.
Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Inoue Y; Noguchi H; Honda N
Oncol Rep; 2007 Jul; 18(1):3-7. PubMed ID: 17549338
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu expression in prostate cancer: a dynamic process?
Carles J; Lloreta J; Salido M; Font A; Suarez M; Baena V; Nogue M; Domenech M; Fabregat X
Clin Cancer Res; 2004 Jul; 10(14):4742-5. PubMed ID: 15269147
[TBL] [Abstract][Full Text] [Related]
10. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
11. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.
Osman I; Scher HI; Drobnjak M; Verbel D; Morris M; Agus D; Ross JS; Cordon-Cardo C
Clin Cancer Res; 2001 Sep; 7(9):2643-7. PubMed ID: 11555574
[TBL] [Abstract][Full Text] [Related]
13. Relation between HER-2 gene expression and Gleason score in patients with prostate cancer.
Mofid B; Jalali Nodushan M; Rakhsha A; Zeinali L; Mirzaei H
Urol J; 2007; 4(2):101-4. PubMed ID: 17701930
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of chromogranin A in Stage D2 prostate cancer.
Kokubo H; Yamada Y; Nishio Y; Fukatsu H; Honda N; Nakagawa A; Saga S; Tsuzuki T; Hara K
Urology; 2005 Jul; 66(1):135-40. PubMed ID: 15992907
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between HER-2/neu over-expression and androgen independent prostate cancer].
Bai Q; Chen F; Qi J; Chen JH; Wang YX
Zhonghua Nan Ke Xue; 2007 May; 13(5):414-6. PubMed ID: 17569256
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
Zhang YF; Guan YB; Yang B; Wu HY; Dai YT; Zhang SJ; Wang JP; Anoopkumar-Dukie S; Davey AK; Sun ZY
Chin Med J (Engl); 2011 Dec; 124(24):4345-9. PubMed ID: 22340411
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas.
Visakorpi T; Kallioniemi OP; Koivula T; Harvey J; Isola J
Mod Pathol; 1992 Nov; 5(6):643-8. PubMed ID: 1369801
[TBL] [Abstract][Full Text] [Related]
19. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme.
Koka V; Potti A; Forseen SE; Pervez H; Fraiman GN; Koch M; Levitt R
Am J Clin Oncol; 2003 Aug; 26(4):332-5. PubMed ID: 12902879
[TBL] [Abstract][Full Text] [Related]
20. Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer.
Yamada Y; Nakamura K; Aoki S; Tobiume M; Zennami K; Kato Y; Nishikawa G; Yoshizawa T; Itoh Y; Nakaoka A; Yoshida E; Uchiyama T; Honda N
Oncol Rep; 2011 Apr; 25(4):937-44. PubMed ID: 21249322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]